Alpine Immune Sciences Inc (ALPN)
NASDAQ:ALPN

Alpine Immune Sciences Stock Analysis & Ratings

ALPN Stock Chart & Stats

Day’s Range$7.72 - $8.19
52-Week Range$6.00 - $15.14
Previous Close$8.01
Volume48.32K
Average Volume (3M)113.91K
Market Cap$242.02M
P/E Ratio-4.1
Beta1.74
Next EarningsAug 16, 2022
Next Dividend Ex-DateN/A
Dividend YieldN/A
Smart Score6
EPS (TTM)-1.97


Financials

Yearly

P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

---

Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.

---

ALPN FAQ

What was Alpine Immune Sciences’s price range in the past 12 months?
Alpine Immune Sciences lowest stock price was $6.00 and its highest was $15.14 in the past 12 months.
    What is Alpine Immune Sciences’s market cap?
    Alpine Immune Sciences’s market cap is $242.02M.
      What is Alpine Immune Sciences’s price target?
      The average price target for Alpine Immune Sciences is $19.00. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $21.00 ,the lowest forecast is $17.00. The average price target represents 138.10% Increase from the current price of $7.98.
        What do analysts say about Alpine Immune Sciences?
        Alpine Immune Sciences’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 3 Wall Streets Analysts.
          When is Alpine Immune Sciences’s upcoming earnings report date?
          Alpine Immune Sciences’s upcoming earnings report date is Aug 16, 2022 which is in 88 days.
            How were Alpine Immune Sciences’s earnings last quarter?
            Alpine Immune Sciences released its earnings results on May 12, 2022. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.168 by -$0.082.
              Is Alpine Immune Sciences overvalued?
              According to Wall Street analysts Alpine Immune Sciences’s price is currently Undervalued.
                Does Alpine Immune Sciences pay dividends?
                Alpine Immune Sciences does not currently pay dividends.
                What is Alpine Immune Sciences’s EPS estimate?
                Alpine Immune Sciences’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Alpine Immune Sciences have?
                Alpine Immune Sciences has 30,330,000 shares outstanding.
                  What happened to Alpine Immune Sciences’s price movement after its last earnings report?
                  Alpine Immune Sciences reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.168. Following the earnings report the stock price went up 12.519%.
                    Which hedge fund is a major shareholder of Alpine Immune Sciences?
                    Among the largest hedge funds holding Alpine Immune Sciences’s share is Omega Fund Management, LLC. It holds Alpine Immune Sciences’s shares valued at 18M.

                      ---

                      Alpine Immune Sciences Stock Analysis

                      The Alpine Immune Sciences stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Alpine Immune Sciences Inc

                      Alpine Immune Sciences, Inc. is a development-stage pharmaceutical company, which engages in the discovering of protein-based immunotherapies therapies targeting the immune synapse to treat cancer, autoimmune, and inflammatory disorders. It offers Immunotherapy, Immune Synapse, vIgD Platform Technology, and TIP Program. The company was founded in 2015 and is headquartered in Seattle, WA.

                      ---
                      Similar Stocks
                      Company
                      Price & Change
                      Follow
                      Corbus Pharmaceuticals
                      Vertex Pharmaceuticals
                      Dynavax
                      ProQR
                      Innoviva

                      Popular Stocks

                      ---
                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis